Compare VISN & ABSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VISN | ABSI |
|---|---|---|
| Founded | 1976 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.4B |
| IPO Year | 2013 | 2021 |
| Metric | VISN | ABSI |
|---|---|---|
| Price | $3.84 | $7.60 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 12 |
| Target Price | $5.67 | ★ $15.09 |
| AVG Volume (30 Days) | ★ 7.1M | 4.3M |
| Earning Date | 11-05-2026 | 11-12-2026 |
| Dividend Yield | ★ 412.50% | N/A |
| EPS Growth | ★ 641.01 | 10.64 |
| EPS | ★ 29.48 | N/A |
| Revenue | ★ $1,931,600,000.00 | $4,534,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $37.25 |
| P/E Ratio | $0.14 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.89 | $2.24 |
| 52 Week High | $19.91 | $12.54 |
| Indicator | VISN | ABSI |
|---|---|---|
| Relative Strength Index (RSI) | 25.48 | 39.21 |
| Support Level | N/A | $6.69 |
| Resistance Level | $6.76 | $11.94 |
| Average True Range (ATR) | 0.25 | 0.92 |
| MACD | -0.09 | -0.28 |
| Stochastic Oscillator | 1.79 | 5.47 |
Vistance Networks Inc operates in the communications technology sector, providing solutions designed to support the delivery and management of communications services. It serves customers globally through teams involved in product development, implementation, and customer support. The company designs and develops network infrastructure and connectivity solutions focused on reliability and performance. Its offerings include intelligent networking technologies intended to support evolving communication requirements.
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process. Its lead product candidate, ABS-201, is an anti-prolactin receptor (PRLR) antibody engineered with an extended half-life to support a patient-friendly dosing interval.